{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:53:42Z","timestamp":1762898022261,"version":"build-2065373602"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":3170,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1996,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The D2 dopamine agonist piribedil is not widely used in the treatment of Parkinson's disease because it was thought to be effective mainly on parkinsonian tremor and to produce a high incidence of peripheral side effects, particular nausea. In this study, we used 1\u2013methyl\u20134\u2013phenyl\u20131,2,3,6\u2013tetrahydropyridine (MPTP)\u2013treated primates to reevaluate the antiparkinsonian ability of piribedil after its oral administration in the presence or absence of domperidone pretreatment. Adult common marmosets <jats:italic>(Callithrix jacchus)<\/jats:italic> were treated with the nigral toxin MPTP to induce a parkinsonian syndrome characterised primarily by brady kinesia and other motor deficits. Oral administration of a solution of piribedil [1\u2013(3,4\u2013methylenedioxybenzyl)\u20134\u2013(2\u2013pyrimidinyl) piperazine] produced a dose\u2013related reversal of all MPTP locomotor and behavioural deficits. However, this effect was short lived and associated with unwanted effects, particular nausea and retching, which clearly hindered locomotion. In contrast, after pretreatment with the peripheral dopamine antagonist domperidone, administration of piribedil did not induce nausea or retching in MPTP\u2010treated marmosets. In these animals, piribedil caused a more marked and and longer lasting enhancement of locomotor activity and a further reduction in behavioural deficits than that observed after administration of piribedil alone. In addition, piribedil induced increased vigilance and awareness. These data show that piribedil can reverse akinesia and rigidity in MPTP\u2010treated primates. In addition, they show the drug to be effective without peripheral side effects when used in conjuction with domperidone. These data indicate that piribedil should be an effective monotherapy for Parkinson's disease.<\/jats:p>","DOI":"10.1002\/mds.870110203","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T09:45:58Z","timestamp":1104486358000},"page":"125-135","source":"Crossref","is-referenced-by-count":35,"title":["An appraisal of the antiparkinsonian activity of piribedil in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated common marmosets"],"prefix":"10.1002","volume":"11","author":[{"given":"Lance","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Salvia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. David","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_1_2_2","DOI":"10.1126\/science.179.4075.816"},{"doi-asserted-by":"publisher","key":"e_1_2_1_3_2","DOI":"10.1111\/j.2042-7158.1973.tb10026.x"},{"doi-asserted-by":"publisher","key":"e_1_2_1_4_2","DOI":"10.1016\/0014-2999(74)90111-3"},{"doi-asserted-by":"publisher","key":"e_1_2_1_5_2","DOI":"10.1016\/0014-2999(83)90053-5"},{"key":"e_1_2_1_6_2","first-page":"175","article-title":"Actions of dopaminergic agonists on cyclic AMP production in rat brain homogenates","volume":"9","author":"Iversen LL","year":"1975","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_7_2","DOI":"10.1016\/0014-2999(72)90149-5"},{"key":"e_1_2_1_8_2","first-page":"285","article-title":"Actions of dopamine agonists on motor function","volume":"9","author":"Costall B","year":"1975","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_9_2","DOI":"10.1111\/j.2042-7158.1971.tb09916.x"},{"doi-asserted-by":"publisher","key":"e_1_2_1_10_2","DOI":"10.1007\/BF00500645"},{"doi-asserted-by":"publisher","key":"e_1_2_1_11_2","DOI":"10.1002\/cpt19741661077"},{"key":"e_1_2_1_12_2","first-page":"367","article-title":"Actions of dopaminergic agonists in parkinsonism","volume":"9","author":"McDowell FH","year":"1975","journal-title":"Adv Neurol"},{"key":"e_1_2_1_13_2","first-page":"373","article-title":"Indications of piribedil in L\u2013Dopa treated parkinsonian patients: physiopathologic implications","volume":"9","author":"Rondot P","year":"1975","journal-title":"Adv Neurol"},{"key":"e_1_2_1_14_2","first-page":"383","article-title":"Dopaminergic agonist effects on parkinsonian clinical features and brain monoamine metabolism","volume":"9","author":"Rinne UK","year":"1975","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_15_2","DOI":"10.1016\/0022-510X(90)90225-C"},{"doi-asserted-by":"publisher","key":"e_1_2_1_16_2","DOI":"10.1136\/jnnp.38.4.331"},{"doi-asserted-by":"publisher","key":"e_1_2_1_17_2","DOI":"10.1212\/WNL.31.6.662"},{"doi-asserted-by":"publisher","key":"e_1_2_1_18_2","DOI":"10.1007\/978-3-642-73899-9_20"},{"doi-asserted-by":"publisher","key":"e_1_2_1_19_2","DOI":"10.1007\/BF02245479"},{"doi-asserted-by":"publisher","key":"e_1_2_1_20_2","DOI":"10.1007\/BF02244377"},{"key":"e_1_2_1_21_2","first-page":"117","article-title":"Piribedil and Parkinson's disease: protection of peripheral side\u2010effects by domperidone","volume":"2","author":"Agnoli A","year":"1981","journal-title":"Clin Pharmacol"},{"issue":"1","key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/BF00819564","article-title":"Activity and acceptability of piribedil in Parkinson's disease","volume":"239","author":"Rondot P","year":"1992","journal-title":"J Neurol"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870110203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870110203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:50:53Z","timestamp":1760957453000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870110203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1996,3]]}},"alternative-id":["10.1002\/mds.870110203"],"URL":"https:\/\/doi.org\/10.1002\/mds.870110203","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}